"The potential of MANF technology has been recognized by some of the biggest names in the biotech space. Just last month, Amarantus announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. "I believe in MANF," said Dr. Rubinfeld. "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously." Dr. Rubinfeld went on to add that MANF has the commercial potential to become a blockbuster drug."
I hope that everyone is adding shares at the current price.
Once the public finds out about the huge potential that the company's patented MANF technology offers you'll regret not having bought more shares at the current "bargain basement price."
Ignore anyone that says this is going lower because it isn't. The bottom was yesterday and yesterday's gone.
The "Human Brain Mapping Project" is going to start generating any number of articles related to what companies will benefit from the project. I have to believe that Amarantus will be at the forefront of those discussions especially as it relates to small-cap bio-tech companies.
I think the recent high of .195 will be surpassed within four weeks or sooner.
A joint venture or partnership takes this to over .50 in a day.
p.s. Be happy that you found out about the company's tremendous upside before 99.9% of the future shareholders.
Note: Amgen (AMGN) was once a seven cent stock. It's currently trading at $86.82.